Fundamental and clinical studies on cefclidin in complicated urinary tract infections

Daisuke Yamada, Tadasu Takenaka, Satosi Uno, Yoshio Nishitani, Noriaki Ono, Kazuhiro Hata, Masaya Tugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Katsuyoshi Kondo, Teruaki Akaeda, Nobuyuki Akazawa, Noritaka Ishido, Mikio Kishi

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and clinical efficacy of cefclidin (CFCL), a new injectable cephem antibiotic. 1. Antibacterial activity: We determined the MICs of CFCL against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of cefoperazone, latamoxef and ceftazidime. Against Enterococcus faecalis, CFCL had weak antibacterial activity. Against other species, especially Pseudomonas aeruginosa, however, antibacterial activity of CFCL were superior to those of the comparative drugs. 2. Clinical efficacy: Thirty-six patients with complicated urinary tract infection were treated twice a day with 0.5g or 1.0g of CFCL. Out of 36, 28 cases were evaluated according to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 53.6%. Bacteriologically, 38 of 46 strains (82.6%) were eradicated. No side effect were observed. In 3 patients, abnormal laboratory findings were noted, but were not problematic clinically.

Original languageEnglish
Pages (from-to)432-439
Number of pages8
Publication statusPublished - Sept 1992


  • Cefclidin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Fundamental and clinical studies on cefclidin in complicated urinary tract infections'. Together they form a unique fingerprint.

Cite this